Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00972712 · ClinicalTrials.gov registry record · Phase 1
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00972712 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 12 participants.
The verdict
NCT00972712, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to test the effect of the combination of bortezomib and tipifarnib. Bortezomib (VELCADE) is approved by the Food and Drug Administration (FDA) for the treatment of multiple myeloma patients who have received at least one prior therapy. Tipifarnib is not yet approved by the FDA and is an investigational drug. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it. Because these drugs have not been used together before, it is not clear which dose of each agent is optimal when used in combination. This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational drug. Phase I studies also try to define the appropriate dose of the investigational drugs to use for further studies. The investigators will test the safety of BORTEZOMIB and TIPIFARNIB together and see what effects (good and bad) it has on you and your MULTIPLE MYELOMA, and to find the highest dose of both agents that can be given without causing severe side effects.
Interventions
- DRUG Bortezomib and Tipifarnib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-12 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00972712
The ClinicalTrials.gov registry entry for NCT00972712 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bortezomib and Tipifarnib is the first listed.
NCT00972712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00972712 about?
NCT00972712 is a clinical study titled "Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma". The purpose of this study is to test the effect of the combination of bortezomib and tipifarnib. Bortezomib (VELCADE) is approved by the Food and Drug Administration (FDA) for the treatment of multiple myeloma patients who have received at least one prior therapy. Tipifarnib is not yet approved by t...
What is the current status of trial NCT00972712?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2006-12. Estimated completion is 2015-03.
What interventions are being tested in trial NCT00972712?
The interventions under investigation include: Bortezomib and Tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00972712?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.